Overview of Drug Benefit-Risk Assessment Research Progress

Abstract

Abstract: Benefit-risk assessment is an important means of ensuring drug safety, so it is particularly important to establish scientific, comprehensive and unified evaluation method and framework. In order to understand the foreign research situation of drug benefit-risk assessment, this article describes the hot topics and research progress among regulatory agencies, industry organizations, as well as enterprise, and further summerises the challenges and prospects of current research areas. Moreover, based on the present situation of our country, the article provides reference for domestic drugs benefit-risk assessment.

Key words: drugs, benefit, risk, assessment

CLC Number:

R951

LU Yu –mei, ZHANG Ming –hui, WU Zhi -ang . Overview of Drug Benefit-Risk Assessment Research Progress [J]. Chinese Journal of Pharmacovigilance, 2013, 10(8): 473-477.

References

[1] Dr Theresa Mullin. US regulator's perspective on risk-benefit considerations[EB/OL].（2010-6-1）.http://cirsci.org/sites/default/ files/1020B% 20CMR% 20International% 20Institute% 20June% 202010%20Workshop.pdf.
[2] Nikolaos Zafiropoulos, Lawrence Phillips, Francesco Pignatti. Evaluating benefit-risk: An Agency perspective [J]. Regulatory Rapporteur.2012, 6 (9):5-8.
[3] EMA.'Benefit-risk methodology project: Work package 1 report: Description of the current practice of benefit-risk assessment for centralised procedure products in the European Union regulatory network'(EMA/227124/2011) [EB/OL].（2011-5-25）. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109478.pdf.
[4] EMA.'Benefit-risk methodology project: Work package2 report: Applicability of current tools and processes for regulatory benefit-risk assessment' (EMA/549682/2010). [EB/OL].（2010-8-31）.http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/
10/WC500097750.pdf.
[5] EMA.'Benefit-risk methodology project: Work package3 report: Field tests'(EMA/718294/2011) [EB/OL].（2011-8-31）. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500112088.pdf.
[6] EMA. 'Benefit-risk methodology project: Work package 4 report: Benefit-risk tools and processes' ( EMA/297405/2012 ) [ EB/OL ].（2012-05-09）.http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/03/WC500123819.pdf.
[7] Stuart Walker, Neil McAuslane, Lawrence Liberti. Developinga common benefit-risk assessment methodology foe medicines-a progress report.[EB/OL].（2011-12-1）. http://cirsci.org/system/files/private/SRA_Dec%202011_Developing_Walker_McAuslane_Liberti% 5B1%5D.pdf.
[8] Dr Petra D?rr. Improving the Benefit-Risk Assessment of Medicines: A "Consortium" Initiative[EB/OL].（2010-6-1）. http://cirsci.org/sites/default/files/1020B% 20CMR% 20International% 20Institute% 20June%202010%20Workshop.pdf.
[9] By Lawrence Liberti, Stuart R. Walker. Progress on the Development of a Benefit/Risk Framework for Evaluating Medicines [EB/OL]. [2010-3].http://cirsci.org/system/files/private/2010FocusLiberti_0.pdf.
[10] PM Coplan, RA Noel, BS Levitan, et al.Development of Communication of the Benefit-Risk Balance of Medicines[EB/OL].（2010-12-1）.http : //cmpi .org/uploads/File/benefit-risk-journalarticle.pdf.
[11] CIRS. Unified Methodologies for Benefit-Risk Assessment (UMBRA) initiative[EB/OL]. http://cirsci.org/UMBRA.
[12] IMI.PROTECT project[EB/OL].[2013-1-1].http://www.imi.europa. eu/#&panel1-5.
[13] IMI. PROTECT. WP5: Benefit-risk integration and representation [EB/OL].[2013-1-1].http://www.imi-protect.eu/wp5.shtml.
[14] Dr Rebecca Noel. Benefit-risk assessment: The Lilly Perspective[EB/OL].（2010-6-1）.http://cirsci.org/sites/default/files/1020B% 20CMR%20International%20Institute%20June%202010%20Workshop.pdf.
[15] Dr Sinan Bardakci Sarac. Novo Nordisk A/S development of abenefit-riskassessment method[EB/OL].（2010-6-1）.http://cirsci.org/sites/default/files/1020B% 20CMR% 20International% 20Institute% 20June%202010%20Workshop.pdf.